More than 50 million people suffer from chronic pain in this country. Left untreated, chronic pain may affect sleep, quality of life, mental health, and productivity. Managed care pharmacists are actively involved in pain management. They optimize treatment strategies to improve patient outcomes and provide colleagues with information regarding administration, side effects, drug interaction potential, and efficacy of pharmacologic agents.

The gold standard for pain associated with cancer is opioid analgesics. The use of these drugs for chronic nonmalignant pain is a controversial topic. Some clinicians are hesitant to prescribe these medications due to concerns about drug addiction, when, in truth, studies have shown that drug addiction is unlikely in patients with no history of it. An important component of the abuse factor is the ability with which the active ingredient may be removed. To minimize abuse there are several compounds in clinical trials that will contribute to the appropriate use of long-acting opioid therapy.

Pharmacists can be instrumental in improving patients’ pain relief. In order to provide optimal care, pharmacists need an in-depth understanding of pain management. This activity will enable managed care pharmacists to optimize regimens for pain, dispel myths surrounding the use of opioids, and provide critical educational information about abuse-resistant technologies.

Brien L. Neudeck, PharmD (Chairperson)
Associate Professor of Clinical Pharmacy
Assistant Professor of Pharmaceutical Sciences
University of Tennessee Health Science Center
College of Pharmacy
Memphis, TN

John P. Barbuto, MD
Director, Neurology in Focus
HealthSouth Rehabilitation Hospital
JMCP Editorial Advisory Board Member
Sandy, UT

Bruce R. Canaday, PharmD, FASHP, FAPhA
Clinical Professor, Director of Pharmacotherapy - Coastal AHEC
Division: Pharmacy Practice and Experiential Education
Wilmington, NC

Kenneth C. Jackson, II, PharmD
Associate Professor
Pacific University
School of Pharmacy
Hillsboro, OR

After attending this symposium, attendees should be better able to:

• Compare and contrast pharmacologic treatment options for chronic pain.
• Identify barriers associated with opioid therapy and methods to overcome these obstacles to optimize treatment.
• Differentiate between new and emerging opioids with abuse-resistant technology and currently available opioids.
• Manage symptom control to improve quality of life in patients with refractory pain.
• Implement newly acquired knowledge and skills of managed care pharmacists (eg, equianalgesic conversion) to optimize patient care.

5:00 - 5:30 PM Registration and Dinner

5:30 - 5:40 PM Introduction
Brien L. Neudeck, PharmD (Chairperson)

5:40 - 5:45 PM ARS Pre-Test
Brien L. Neudeck, PharmD

5:45 – 6:15 PM Current State of Chronic Pain Management
John P. Barbuto, MD

6:15 – 6:45 PM New and Emerging Therapies in Chronic Pain
Kenneth C. Jackson, II, PharmD

6:45 – 7:15 PM Perspectives for the Managed Care Pharmacist
Bruce R. Canaday, PharmD, FASHP, FAPhA

7:15 – 7:25 PM Conclusion
Brien L. Neudeck, PharmD

7:25 – 7:30 PM ARS Post-Test
Brien L. Neudeck, PharmD

Accreditation Statement
The University of Tennessee College of Pharmacy (UTCOP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) to provide continuing education for pharmacists.

Credit Designation Statement

This program will provide 2 live contact hours credit (0.2 CEUs) and is sponsored by the University of Tennessee College of Pharmacy who is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. A statement of CE credit will be mailed within 4 weeks following successful completion of the program. Successful completion includes attending the session, signing the attendance sheet, and completion of the program evaluation form.

ACPE Program # 064-000-08-204-L01-P.

This program is available at no charge.

Intended Audience
This activity is designed for managed care pharmacists.

Policy on Faculty and Provider Disclosure
It is the policy of the University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the course handout materials.

Americans with Disabilities Act
The University of Tennessee College of Pharmacy fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.

Grievance Policy
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of a program sponsored or cosponsored by the UTCOP may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level of review.